Pharmaceutical and medicine manufacturing total R&D performance vs Alzheimer's disease drug trial starts in United States
In 2023, pharmaceutical and medicine manufacturing total R&D performance in United States was 125,986 million USD; alzheimer's disease drug trial starts was 30.
Change the pair
Compare different indicators
The series
Over time
United States, annual figures, spaced by time from 2022 to 2023 . Different units, drawn on separate scales and clipped to the years both series publish; earlier history stays on each indicator’s own page. Read the values, not the heights.
Pharmaceutical and medicine manufacturing total R&D performance
Unit: million USD · 2 observations
Alzheimer's disease drug trial starts
Unit: count · 2 observations
Shared periods
Side by side
2 periods are published for both series in United States as annual figures on the same basis. Comparing anything else would mean comparing different periods.
| Period | Pharmaceutical and medicine manufacturing total R&D performance | Alzheimer's disease drug trial starts |
|---|---|---|
| 2022 | 116,073 million USD NCSES | 50 ClinicalTrials.gov |
| 2023 | 125,986 million USD NCSES | 30 ClinicalTrials.gov |
Provenance
Where these numbers come from
Pharmaceutical and medicine manufacturing total R&D performance
Total cost of research and development performed by pharmaceutical and medicine manufacturing companies across all funding sources.
2 observations charted in United States · source organisations: NCSES
Alzheimer's disease drug trial starts
Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
2 observations charted in United States (of 6 annual records) · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring